Form 4: Foghorn Therapeutics Director Michael Mendelsohn Acquires 25,000 Stock Options

Foghorn Therapeutics Inc. Director Michael Mendelsohn reported the acquisition of 25,000 stock options at an exercise price of $4.79 per share, exercisable from June 17, 2026, as disclosed in a recent SEC Form 4 filing.

Summary

• The filing is a U.S. Securities and Exchange Commission (SEC) Form 4, reporting a change in beneficial ownership of securities.
• The reporting person is Michael Mendelsohn, identified as a Director of Foghorn Therapeutics Inc. (FHTX).
• On June 17, 2025, Mr. Mendelsohn acquired 25,000 derivative securities in the form of stock options.
• Each stock option has an exercise price of $4.79.
• The options become exercisable on June 17, 2026, and have an expiration date of June 16, 2035.
• The underlying security for these options is 25,000 shares of Common Stock.
• Following this reported transaction, Michael Mendelsohn beneficially owns 25,000 derivative securities.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director typically signals confidence in the company's future performance and aligns management's interests with shareholders, which is generally viewed positively.

Positives

• The acquisition of stock options by a director can be interpreted as a positive signal, indicating management's confidence in the company's future prospects and aligning their interests with shareholders.

Related Party Transactions

• The reported acquisition of 25,000 stock options by Director Michael Mendelsohn is a related party transaction, as it involves a company insider.

Stakeholder Impact

• Shareholders may view the director's acquisition of options as a positive signal of confidence in the company's future, potentially influencing investor sentiment.

Next Steps

• The acquired stock options will become exercisable on June 17, 2026.

Key Dates

Keywords

Foghorn Therapeutics, FHTX, SEC Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Director, Michael Mendelsohn